The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cellectar Biosciences Inc shares valued at $732 were sold by NEIS JOHN on Dec 12 ’25. At $3.70 per share, NEIS JOHN sold 198 shares. The insider’s holdings dropped to 10 shares worth approximately $29.5 following the completion of this transaction.
Also, CARUSO JAMES V purchased 10,000 shares, netting a total of over 49,900 in proceeds. Following the buying of shares at $4.99 each, the insider now holds 11,638 shares.
Before that, Longcor Jarrod had added 10,000 shares to its account. In a trade valued at $49,900, the Chief Operating Officer bought Cellectar Biosciences Inc shares for $4.99 each. Upon closing the transaction, the insider’s holdings increased to 10,000 shares, worth approximately $37665.600000000006.
Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early July. Earlier on September 13, 2019, ROTH Capital initiated its rating. Their recommendation was “a Buy” for CLRB stock.
Analyzing CLRB Stock Performance
On last trading session, Cellectar Biosciences Inc [NASDAQ: CLRB] rose 7.66% to $2.95. The stock’s lowest price that day was $2.7, but it reached a high of $3.005 in the same session. During the last five days, there has been a surge of approximately 9.67%. Over the course of the year, Cellectar Biosciences Inc shares have dropped approximately -68.16%. Shares of the company reached a 52-week high of $20.60 on 06/04/25 and a 52-week low of $2.45 on 12/17/25.
Support And Resistance Levels for Cellectar Biosciences Inc (CLRB)
According to the 24-hour chart, there is a support level at 2.77, which, if violated, would cause prices to drop to 2.58. In the upper region, resistance lies at 3.07. The next price resistance is at 3.19. RSI (Relative Strength Index) is 45.29 on the 14-day chart, showing neutral technical sentiment.
Is Cellectar Biosciences Inc subject to short interest?
Stocks of Cellectar Biosciences Inc saw a sharp steep in short interest on 2025-12-15 dropping by 83788.0 shares to 0.11 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 0.19 million shares. A decline of -79.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.98 of the overall float, the days-to-cover ratio (short ratio) decline to 1.98.
Which companies own the most shares of Cellectar Biosciences Inc (CLRB)?
In terms of Cellectar Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 12 in the next 12 months, up nearly 337.96% from the previous closing price of $2.74. Analysts anticipate Cellectar Biosciences Inc stock to reach 12 by 2026, with the lowest price target being 12. In spite of this, 1 analysts ranked Cellectar Biosciences Inc stock as Buy at the end of 2026. On December 21, 2016, Ladenburg Thalmann assigned a price target of “a Buy” to the stock and initiated coverage with a $2.70.
